Differential expression of serum miR-486 and miR-25 in ulcerative colitis and Crohn’s disease: Correlations with disease activity, extent, and location

Abdelazim, Samy A.; Shaker, Olfat G.; Ali, Omaima; El-Tawil, Mai; Senousy, Mahmoud A.

doi:10.1016/j.prp.2023.154910

Cited by 2 publications

(1 citation statement)

References 47 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Several articles have recently shown miRNAs as a new biomarker of inflammation in inflammatory bowel disease (IBD) [59][60][61]. In this sense, Abdelazim et al 2023 explain that serum miR-486 could be employed in the risk stratification of IBD subtypes and has grounds for clinical utility in Crohn's disease (CD) diagnosis, whereas miR-25 has the potential for ulcerative colitis (UC) and CD diagnosis.…”

Section: Micrornas As Circulating Biomarkers In Health and Diseasementioning

confidence: 99%

MicroRNAs as Potential Graft Rejection or Tolerance Biomarkers and Their Dilemma in Clinical Routines Behaving like Devilish, Angelic, or Frightening Elements

Legaz,

Jimenez-Coll,

González-López

et al. 2024

Biomedicines

View full text Add to dashboard Cite

Allograft rejection is a widespread complication in allograft recipients with chronic kidney disease. Undertreatment of subclinical and clinical rejection and later post-transplant problems are caused by an imperfect understanding of the mechanisms at play and a lack of adequate diagnostic tools. Many different biomarkers have been analyzed and proposed to detect and monitor these crucial events in transplant outcomes. In this sense, microRNAs may help diagnose rejection or tolerance and indicate appropriate treatment, especially in patients with chronic allograft rejection. As key epigenetic regulators of physiological homeostasis, microRNAs have therapeutic potential and may indicate allograft tolerance or rejection. However, more evidence and clinical validation are indispensable before microRNAs are ready for clinical prime time.

show abstract

Section: Micrornas As Circulating Biomarkers In Health and Diseasementioning

confidence: 99%

MicroRNAs as Potential Graft Rejection or Tolerance Biomarkers and Their Dilemma in Clinical Routines Behaving like Devilish, Angelic, or Frightening Elements

Legaz,

Jimenez-Coll,

González-López

et al. 2024

Biomedicines

View full text Add to dashboard Cite

show abstract

The miRNA Landscape in Crohn's disease: Implications for novel therapeutic approaches and interactions with Existing therapies

Moustafa,

Elsakka,

Abulsoud

et al. 2024

Experimental Cell Research

View full text Add to dashboard Cite

Differential expression of serum miR-486 and miR-25 in ulcerative colitis and Crohn’s disease: Correlations with disease activity, extent, and location

Cited by 2 publications

References 47 publications

MicroRNAs as Potential Graft Rejection or Tolerance Biomarkers and Their Dilemma in Clinical Routines Behaving like Devilish, Angelic, or Frightening Elements

MicroRNAs as Potential Graft Rejection or Tolerance Biomarkers and Their Dilemma in Clinical Routines Behaving like Devilish, Angelic, or Frightening Elements

The miRNA Landscape in Crohn's disease: Implications for novel therapeutic approaches and interactions with Existing therapies

Contact Info

Product

Resources

About